in its filing to the exchanges on Monday informed that the company along with its subsidiary launched Testosterone Gel 1.62%, a therapeutic equivalent generic version of AndroGel (testosterone gel) 1.62%, approved by the US Food and Drug Administration (USFDA).
As per IQVIA Health data, the AndroGel (testosterone gel) brand and generic had US sales of ~$815.6mn MAT for the most recent twelve months ending in February 2019, the company said in a press note released today.
"DrRaddy's Testosterone Gel 1.62% (20.25 mg/1.25 g pump actuation) is available in a net quantity of 88 g pump which dispenses 20.25 mg of testosterone per actuation. Each metered-dose pump is capable of dispensing 60 metered pump actuations," the company added.
Dr. Reddy's Laboratories Ltd's share price is currently at Rs2,911, up by Rs7.1 or 0.24%, from its previous close of Rs2,903.90 on the BSE.
The scrip opened at Rs2,887.60 and has touched a high and low of Rs2,926.20 and Rs2,887.60, respectively. So far, 3,71,221 (NSE+BSE) shares have been traded on the counter. The current market cap of the company is Rs48,223.89cr.